Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2140 | Limbix Spark Wiki | 0.71 |
| drug4719 | self-administered questionnaire Wiki | 0.41 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D019337 | Hematologic Neoplasms NIH | 0.25 |
| D003866 | Depressive Disorder NIH | 0.13 |
| D003863 | Depression, NIH | 0.08 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001909 | Leukemia HPO | 0.19 |
| HP:0000716 | Depressivity HPO | 0.13 |
Navigate: Correlations HPO
There are 2 clinical trials
The purpose of this study is to determine which of two approaches is helpful to support caregivers of patients undergoing Hematopoietic Stem Cell Transplant (HSCT) or Chimeric Antigen Receptors (CAR) T-cell therapy at Seidman Cancer Center. This study will take start before you begin treatment until 2 months after your hospital discharge.
Description: Feasibility, as measured by time to identify and recruit dyads (benchmark 3 months)
Measure: Time to identify and recruit dyads in months Time: 2 months post-hospital discharge, an average of 2 monthsDescription: Feasibility, as measured by accrual rates of eligible participants
Measure: Accrual rates Time: 2 months post-hospital discharge, an average of 2 monthsDescription: Feasibility, as measured by retention rate
Measure: Retention rate Time: 2 months post-hospital discharge, an average of 2 monthsDescription: Feasibility as measured by completion of data collection across study timepoints
Measure: Data collection completion rate Time: 2 months post-hospital discharge, an average of 2 monthsDescription: Acceptability, as measured by average acceptability scale scores, with overall score ranging from 6-30. According to prior research, a score of 80% of higher (total score of 24 or higher) is considered acceptable for use.
Measure: Average acceptability scale scores Time: 2 months post-hospital discharge, an average of 2 monthsDescription: Usability, as measured by average System Usability Scale scores. This is a 10 item scale scored on a 5 point Likert scale with total summed scores ranging from 0-50. Total scores are multiplied by 2 to produce an overall score ranging from 0-100 with scores > 68 considered to be above average usability.
Measure: Average System Usability Scale scores Time: 2 months post-hospital discharge, an average of 2 monthsDescription: Caregiver satisfaction will be evaluated by having caregivers evaluate their satisfaction with each of the 6 modules at the end of each module. After completing each module, they will be sent via REDCap a single item evaluation scale (0 -10; 0=Not at all satisfied; 10=Highly satisfied). Scores >7 will be considered acceptable. Mean and standard deviation to describe subjects' overall satisfaction with the intervention reported.
Measure: Mean caregiver satisfaction Time: 2 months post-hospital discharge, an average of 2 monthsDescription: End-of-study caregiver satisfaction, as measured by end of study exit interview that assesses overall satisfaction with intervention (Likert Scale). Scores range from 0 to 10, with higher scores indicating more satisfaction.
Measure: End-of-study caregiver satisfaction scores Time: 2 months post-hospital discharge, an average of 2 monthsDescription: Caregiver anxiety as measured by PROMISR Short Form v1.0 - Anxiety scores. Scores range from 1 to 5, with higher scores indicating worse anxiety. Evaluated for changes over 3 time points using repeated measures analysis of variance (RMANOVA)-between and within model- controlling for caregiver age, race, and gender
Measure: Caregiver anxiety as measured by PROMISR Short Form v1.0 - Anxiety scores Time: Baseline, hospital discharge, 2 months post hospital dischargeDescription: Caregiver HRQOL, evaluated for changes over 3 time points using repeated measures analysis of variance (RMANOVA)-between and within model- controlling for caregiver age, race, and gender. HRQOL scores range from 1 to 5, with higher scores indicating better outcomes.
Measure: Caregiver Healthcare Related Quality Of Life (HRQOL) Time: Baseline, hospital discharge, 2 months post hospital dischargeDescription: Distress as measured by the NCCN distress thermometer. Thermometer scores range from 0 to 10, with higher scores indicating worse distress. Prior to administration of the distress thermometer measure, each caregiver will be asked if they are experiencing distress related to Covid-19 (yes/no). The distress thermometer asking them to rate their distress in the past week including today. The Covid-19 variable will be included as a covariate in the analyses. Evaluated for changes over 3 time points using repeated measures analysis of variance (RMANOVA)-between and within model- controlling for caregiver age, race, and gender
Measure: Distress as measured by the the NCCN distress thermometer Time: Baseline, hospital discharge, 2 months post hospital dischargeOver 3 million teenagers in the USA have depression, and rates of depression and suicide are sharply increasing. Teenage depression has far-reaching consequences including impairments in academic and work performance and social and family relationships, substance abuse, and worsening of other health conditions, which can persist into adulthood. Access to mental health care for teenagers is limited due to a shortage of mental health providers and many teenagers and parents are reluctant to take antidepressants. COVID-19 and mandated physical and social distancing is expected to increase rates of teenage depression, and further limit access to traditional methods of care (e.g. psychotherapy). This highlights an urgent need to develop accessible, digital treatments for teenage depression to address the serious mental health impacts of the COVID-19 pandemic. This fully virtual study (https://www.limbix.com/spark) will compare the relative safety, effectiveness, and engagement of a mobile application based on cognitive behavioral therapy and behavioral activation (Limbix Spark), focusing on the idea that engaging in behaviors that are rewarding or provide a sense of mastery can be effective in reducing symptoms of depression. Limbix Spark will be compared to a mobile app containing educational material about depression (Psychoeducation).
Description: Change in depressive symptoms measured by Personal Health Questionnaire (PHQ-8) (min: 0; max: 24, with higher score indicating more severe depression).
Measure: Change in depressive symptoms Time: Change from Baseline to Post treatment (5 weeks)Description: Change in anxiety symptoms measured by the Generalized Anxiety Disorder (GAD-7) scale (min: 0; max: 21, with higher score indicating more severe anxiety).
Measure: Change in anxiety symptoms Time: Change from Baseline to Post treatment (5 weeks)Description: Change in parent report of child depressive symptoms measured by the Mood and Feelings Questionnaire (MFQ) (min: 0; max: 26, with higher score indicating more severe depression)
Measure: Change in parent report of child depressive symptoms Time: Change from Baseline to Post treatment (5 weeks)Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports